DNA - NYSE

Ginkgo Bioworks Holdings, Inc.

DNA·NYSE

$8.73

-6.4%

HealthcareBiotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$570.28M

EPS-5.6400

P/E Ratio-1.55

Earnings Date08/06/2026

1.12B

Assets

-19%

3Y-56.0%

5Y+66.0%

10Y+61.0%

611.11M

Total Liabilities

-8%

3Y-24.0%

5Y+198.0%

10Y+213.0%

508.59M

Total Equity

-29%

3Y-71.0%

5Y+8.0%

10Y+1.0%

Ginkgo Bioworks Holdings, Inc. Funding & Solvency Profile

DNA · NYSE

Current Assets

Cash & Cash Equivalents167.20M

Net Receivables24.03M

Inventory0.00

Other Current Assets25.19M

Total Current Assets472 M

Non-Current Assets

Property, Plant & Equipment528.70M

Goodwill & Intangible Assets56.92M

Long-Term Investments15.07M

Other Non-Current Assets47.17M

Total Non-Current Assets591 M

Total Assets

1.12B

Financial Health Analysis

Current Ratio

4.92x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.20x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

376 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

42% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Ginkgo Bioworks Holdings, Inc. Balance Sheet

DNA • NYSE

Ginkgo Bioworks Holdings, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	167.2M	561.6M	944.1M	1.3B	1.6B	380.8M	495.3M
Short-Term Investments	255.4M	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	422.6M	561.6M	944.1M	1.3B	1.6B	380.8M	495.3M
Net Receivables	24M	22.4M	17.9M	84M	149.9M	21.9M	7.7M
Accounts Receivables	24M	21.9M	17.2M	82.5M	131.5M	21.9M	7.7M
Other Receivables	0.0	586K	742K	1.6M	18.4M	0.0	0.0
Inventory	0.0	0.0	46K	4.4M	3.4M	9.3M	0.0
Prepaids	0.0	0.0	20.7M	37.2M	19.1M	10.9M	2.6M
Other Current Assets	25.2M	18.7M	19M	8.7M	698K	3.7M	6.4M
Total Current Assets	471.8M	602.7M	1B	1.5B	1.7B	426.5M	511.9M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	528.7M	598.2M	395M	718.8M	145.8M	121.4M	63.1M
Goodwill	0.0	0.0	49.2M	60.2M	21.3M	1.9M	1.9M
Intangible Assets	56.9M	72.5M	82.7M	111M	21.6M	3.3M	3.8M
Goodwill & Intangible Assets	56.9M	72.5M	132M	171.3M	43M	5.2M	5.7M
Long-Term Investments	15.1M	48.7M	77.9M	111.8M	115.2M	103.1M	107.3M
Other Non-Current Assets	47.2M	55.3M	58.7M	87.4M	44M	18.9M	9.3M
Total Non-Current Assets	647.9M	774.7M	663.6M	1.1B	347.9M	248.6M	185.4M
Total Assets	1.1B	1.4B	1.7B	2.5B	2.1B	675.2M	697.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	10.6M	14.2M	9.3M	10.5M	8.2M	13.9M	2.4M
Accounts Payable	10.6M	14.2M	9.3M	10.5M	8.2M	13.9M	2.4M
Accrued Expenses	0.0	6.9M	34.2M	32.9M	52.3M	17.7M	13.6M
Capital Lease Obligations (Current)	0.0	29M	17.5M	29.3M	747K	485K	598K
Deferred Revenue	18.9M	30.6M	48.5M	47.8M	33.2M	0.0	0.0
Other Current Liabilities	66.5M	26.6M	54.4M	52.5M	40.3M	41.1M	23.4M
Total Current Liabilities	96M	107.3M	163.9M	173M	134.8M	73.2M	40.1M
NON-CURRENT LIABILITIES
Long Term Debt	417.1M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	98.8M	158.1M	174.8M	156M	0.0	0.0
Other Non-Current Liabilities	98.1M	16.6M	24.4M	42.1M	190.6M	115.4M	138.6M
Total Non-Current Liabilities	515.1M	554.1M	404.3M	630.1M	368.9M	131.9M	155.4M
Capital Lease Obligations	0.0	467.7M	239.3M	442.6M	23M	17M	17.4M
Total Liabilities	611.1M	661.4M	568.2M	803M	503.6M	205.1M	195.5M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	177K
Common Stock	6K	5K	5K	190K	161K	129K	79K
Additional Paid-In Capital	0.0	6.6B	6.4B	6.1B	3.8B	929.1M	834.1M
Retained Earnings	-6.2B	-5.8B	-5.3B	-4.4B	-2.3B	-467.9M	-341.3M
Accumulated Other Comprehensive Income/Loss	1.9M	-1.8M	1.5M	-2.6M	-1.7M	0.0	0.0
Other Total Stockholders' Equity	6.7B	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	508.6M	716.1M	1.1B	1.7B	1.5B	461.4M	493.1M
Total Equity	508.6M	716.1M	1.1B	1.7B	1.6B	470.1M	501.9M
Minority Interest	0.0	0.0	0.0	0.0	62M	8.7M	8.8M
SUMMARY
Total Liabilities & Equity	1.1B	1.4B	1.7B	2.5B	2.1B	675.2M	697.3M
Total Investments	270.5M	48.7M	77.9M	111.8M	115.2M	103.1M	107.3M
Total Debt	417.1M	467.7M	239.3M	442.6M	23M	17M	17.4M
Net Debt	249.9M	-93.8M	-704.8M	-873.2M	-1.5B	-363.8M	-477.9M
Shares Outstanding	54,646,293	54,646,293	54,646,293	54,646,293	54,646,293	54,646,293	54,646,293

SEC Filings

DNA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 29, 2026	June 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 07, 2026	April 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 27, 2026	February 26, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 23, 2025	December 18, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing

Showing 1 to 10 of 116 filings

Related Guides

Blog Categories

Continue your DNA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.